# antibodies -online.com





## anti-TNFRSF12A antibody

2 Images

3

**Publications** 



Go to Product page

### Overview

Quantity:	0.1 mg
Target:	TNFRSF12A
Reactivity:	Human, Mouse
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This TNFRSF12A antibody is un-conjugated
Application:	Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))

### **Product Details**

Immunogen:	human CD266-transfected P815 cells
Clone:	ITEM-4
Isotype:	lgG2b
Specificity:	The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
Cross-Reactivity (Details):	Human, Mouse
Purification:	Purified by protein-A affinity chromatography.
Purity:	> 95 % (by SDS-PAGE)


## **Target Details**

Target:	TNFRSF12A
Alternative Name:	CD266 / TWEAK R (TNFRSF12A Products)
Background:	TNF receptor superfamily member 12A,CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.,TWEAKR, FN14, TNFRSF12A
Gene ID:	51330
UniProt:	Q9NP84
Pathways:	Apoptosis, Regulation of Cell Size
Application Details	
Application Notes:	Flow cytometry: Recommended dilution: 1-4 μg/mL
Restrictions:	For Research Use only
Handling	
Concentration:	1 mg/mL
Buffer:	Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C
Storage Comment:	Store at 2-8°C. Do not freeze.
Publications	
Product cited in:	Yoriki, Akashi, Sho, Nomi, Yamato, Hotta, Takayama, Matsumoto, Wakatsuki, Migita, Yagita, Nakajima: "Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: <b>Experimental and therapeutic medicine</b> , Vol. 2, Issue 1, pp. 103-108, (2012) ( PubMed).

Roos, Wicovsky, Müller, Salzmann, Rosenthal, Kalthoff, Trauzold, Seher, Henkler, Kneitz, Wajant: "Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway." in: **Journal of immunology (Baltimore, Md.: 1950)**, Vol. 185, Issue 3, pp. 1593-605, (2010) (PubMed).


Nakayama, Ishidoh, Kojima, Harada, Kominami, Okumura, Yagita: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: **Journal of immunology (Baltimore, Md.: 1950)**, Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).

## Images



## Flow Cytometry

**Image 1.** Flow cytometry surface staining pattern of HUVEC cells stained using anti-human CD266 (ITEM-4) purified antibody (concentration in sample 1 μg/mL) GAM APC.



#### **Flow Cytometry**

**Image 2.** Separation of HUVEC cells stained using anti-human CD266 (ITEM-4) purified antibody (concentration in sample 1  $\mu$ g/mL, GAM APC, red-filled) from HUVEC cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).